following an abbreviated submission:
ponesimod (Ponvory®) is accepted for restricted use within NHSScotland.
Indication under review: the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
SMC restriction: Adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features, suitable for or requesting an oral treatment.
Ponesimod offers an additional treatment choice in the therapeutic class of sphingosine-1-phosphate receptor modulators.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
Download detailed advice726KB (PDF)
Medicine details
- Medicine name:
- ponesimod (Ponvory)
- SMC ID:
- SMC2384
- Indication:
For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 08 November 2021